Sunshine Competitors

Stocks . USA . 
Stock . Sunshine Biopharma
SBFM Stock  USD 1.20  0.05  4.35%   
Sunshine Biopharma competes with Biofrontera, CbdMD, Evoke Pharma, HCW Biologics, and Inspira Technologies; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Sunshine Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Sunshine Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Sunshine Biopharma Correlation with its peers.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.

Sunshine Biopharma vs Acurx Pharmaceuticals Correlation

Poor diversification

The correlation between Sunshine Biopharma and ACXP is 0.65 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sunshine Biopharma and ACXP in the same portfolio, assuming nothing else is changed.

Moving against Sunshine Stock

  0.6IMMP Immutep Ltd ADRPairCorr
  0.46KYTX Kyverna TherapeuticsPairCorr
  0.4463E ONWARD MEDICAL BVPairCorr
  0.41DSGN Design TherapeuticsPairCorr
  0.33ENGN enGene Holdings CommonPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.061.224.09
Details
Intrinsic
Valuation
LowRealHigh
0.132.605.47
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Sunshine Biopharma. Your research has to be compared to or analyzed against Sunshine Biopharma's peers to derive any actionable benefits. When done correctly, Sunshine Biopharma's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Sunshine Biopharma.

Sunshine Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sunshine Biopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Sunshine and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sunshine Biopharma does not affect the price movement of the other competitor.

High positive correlations

ACXP
+ 0.92
HCWB
ACXP
+ 0.57
IINN
EVOK
+ 0.51
YCBD
HCWB
+ 0.48
BFRI
LUCY
+ 0.45
IINN
ACXP
+ 0.42
LUCY
  

High negative correlations

IINN
- 0.58
EVOK
ACXP
- 0.57
EVOK
PFSA
- 0.55
IINN
CHEK
- 0.53
BFRI
LUCY
- 0.5
EVOK
HCWB
- 0.49
EVOK

Risk-Adjusted Indicators

There is a big difference between Sunshine Stock performing well and Sunshine Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sunshine Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BFRI  3.74 (0.47) 0.00 (0.11) 0.00 
 0.00 
 6.76 
(7.59)
 34.13 
YCBD  9.24  0.90  0.13  0.28  7.77 
(15.59)
 21.17 
(14.98)
 112.24 
EVOK  4.79  1.93  0.60  0.82  1.69 
(5.72)
 6.93 
(3.91)
 130.92 
HCWB  5.07 (1.76) 0.00 (0.85) 0.00 
 0.00 
 13.02 
(11.97)
 41.72 
IINN  3.42 (0.32) 0.00 (0.30) 0.00 
 0.00 
 7.29 
(7.14)
 24.08 
CHEK  9.87  3.37  0.41 (0.57) 6.07 
(13.88)
 17.16 
(10.37)
 198.26 
LUCY  5.35 (0.11) 0.00  0.34  0.00 
 0.00 
 14.00 
(9.83)
 57.39 
SNOA  2.10 (0.30) 0.00 (0.57) 0.00 
 0.00 
 5.03 
(4.37)
 19.00 
PFSA  212.10  99.20  8.43  1.12  8.88 
(319.17)
 15.67 
(17.65)
 7,142 
ACXP  4.54 (1.20) 0.00 (0.55) 0.00 
 0.00 
 10.84 
(8.06)
 49.19 

Sunshine Biopharma Competitive Analysis

The better you understand Sunshine Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sunshine Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sunshine Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SBFM BFRI YCBD EVOK HCWB IINN CHEK LUCY SNOA PFSA
 4.35 
 1.20 
Sunshine
 2.38 
 0.82 
Biofrontera
 2.13 
 0.92 
CbdMD
 1.15 
 25.70 
Evoke
 5.05 
 1.04 
HCW
 9.23 
 0.71 
Inspira
 2.55 
 1.61 
Check
 18.37 
 1.16 
Innovative
 0.98 
 3.03 
Sonoma
 7.79 
 4.43 
Profusa
Market Volatility
(90 Days Market Risk)
Unstable
Dangerous
Out of control
Moderately volatile
Moderately volatile
Very risky
Abnormally volatile
Extremely Dangerous
Slightly risky
Out of control
Market Performance
(90 Days Performance)
Weakest
Weakest
Mild
Fair
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Risky
High
Strong
Risky
Risky
Hazard
Fair
Risky
Strong
Current Valuation
(Equity Enterprise Value)
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Not Available
Buy
Strong Buy
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Buy
Cautious Hold
Strong Sell
Not Rated
Strong Sell
Cautious Hold
Strong Sell
Current Ratio
401.11
3.16
3.47
10.65
30.25
10.16
13.04
0.34
3.05
N/A
Net Asset
30.56 M
22.1 M
10.42 M
17.52 M
30.24 M
8.07 M
377 K
9.84 M
13.69 M
3.07 M
Profit Margin
-0.17
-0.47
-0.0796
-0.36
N/A
N/A
N/A
N/A
-0.21
N/A
EBITDA
(5.15 M)
(14.44 M)
(244.98 K)
353.31 K
(27.68 M)
(11.1 K)
(9.3 M)
(7.62 M)
(3.57 M)
(4.81 M)
Operating Margin
-0.11
-0.9
-0.2
-0.27
-528.87
-25.03
N/A
-2.87
-0.0601
-61.49
Current Valuation
(2.55 M)
11.38 M
8.21 M
12.48 M
9.15 M
24.07 M
9.35 M
(1.79 M)
2.65 M
17.88 M
Price To Book
0.24
0.65
1.34
5.64
2.8
20.0
0.25
0.61
1.36
N/A
Retained Earnings
(69.04 M)
(117.41 M)
(179.44 B)
(128.79 M)
(100.56 M)
(66.57 M)
(170.01 M)
(24.74 M)
(197.81 M)
(124.96 M)
Current Asset
23 K
N/A
N/A
9.52 M
N/A
N/A
14 M
7.51 M
12.89 M
N/A
Beta
0.73
0.63
2.21
-0.14
0.64
2.26
0.46
3.25
1.66
-0.22
Number Of Employees
52
92
42
3
36
38
12
11
8
N/A
Shares Outstanding
4.91 M
11.65 M
8.91 M
1.72 M
2.15 M
35.95 M
5.85 M
5.35 M
1.7 M
41.76 M
Cash Flow From Operations
(12.53 M)
(10.27 M)
(1.45 M)
(5.46 M)
(14.23 M)
(9.37 M)
(8 M)
(6.74 M)
(88 K)
(2.07 M)
Total Debt
952.48 K
4.92 M
778.24 M
5.16 M
13.69 M
2.51 M
1.83 M
743.17 K
305 K
48.21 M
Return On Equity
-0.26
-11.92
-0.33
-1.35
-277.26
-3.39
-2.26
-0.74
-0.76
N/A
Return On Asset
-0.11
-0.65
-0.0944
-0.22
-0.3
-1.14
-0.47
-0.45
-0.14
N/A
Number Of Shares Shorted
307.25 K
251.79 K
229.56 K
6.99 K
21.44 K
283.91 K
181.37 K
435 K
28.47 K
3.01 M
Book Value Per Share
5.64
-0.22
0.69
1.56
-0.024
0.045
-0.25
1.97
2.3
-22.16
Current Liabilities
277 K
N/A
N/A
1.83 M
N/A
N/A
1000 K
5.78 M
3.55 M
N/A
Total Asset
30.56 M
22.1 M
10.42 M
17.52 M
30.24 M
8.07 M
377 K
9.84 M
13.69 M
3.07 M
Debt To Equity
8.98
N/A
0.11
0.7
0.005
0.078
0.02
N/A
0.12
N/A
Short Ratio
0.5
0.63
0.19
0.03
0.54
1.57
1.51
0.05
1.26
0.57
Target Price
7.0
6.0
2.0
18.0
35.0
5.0
7.0
3.0
13.4
N/A
Shares Owned By Institutions
2.61
25.49
5.63
25.05
2.24
3.64
0.67
6.99
4.04
1.6
Market Capitalization
8.19 M
9.56 M
6.58 M
18.95 M
5.36 M
25.64 M
9.42 M
6.21 M
5.15 M
7.85 M
Price To Earning
1.07
N/A
17.62
-3.21
N/A
N/A
-2.47
N/A
2.57
N/A
Price To Earnings To Growth
N/A
N/A
N/A
-0.1
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
0.16
0.26
0.5
1.31
8.08
88.72
N/A
2.59
0.3
104.68
Net Income
(5.13 M)
(17.76 M)
(2.04 B)
(5.35 M)
(30.02 M)
(11.05 M)
(25.15 M)
(7.77 M)
(3.46 M)
(9.23 M)
Earnings Per Share
-15.02
-1.5
0.51
-1.38
-16.41
-0.48
-4.27
-2.03
-2.01
-0.53
Shares Owned By Insiders
2.94
12.18
16.0
10.62
27.3
6.27
20.81
11.61
1.18
26.36
Revenue
34.87 M
37.3 M
19.19 M
10.25 M
2.57 M
N/A
N/A
1.64 M
14.29 M
N/A
Working Capital
19.65 M
8.68 M
3.36 M
6.86 M
(23.93 M)
3.44 M
(1.55 M)
8.5 M
8.55 M
(56.87 M)
Cash And Equivalents
41.74 M
31.91 M
10.55 M
13.45 M
32.41 M
19.17 M
49.84 M
34.88 K
5.59 M
N/A
Cash Per Share
2.21
1.36
0.17
4.02
0.9
1.9
0.43
N/A
1.8
N/A
Gross Profit
12.11 M
23.94 M
11.64 M
13.99 M
166.57 K
2 K
N/A
546.42 K
6.38 M
75 K
Day Typical Price
1.19
0.84
0.92
25.75
1.02
0.71
1.59
1.11
3.05
4.27
Accumulation Distribution
0.0574
0.0795
0.0937
0.0399
0.0943
0.13
0.1
0.14
0.0633
0.14
Market Facilitation Index
0.07
0.07
0.09
1.05
0.1
0.1
0.17
0.16
0.2
0.62
Daily Balance Of Power
0.7143
(0.29)
(0.22)
(0.29)
0.5
0.6
0.2353
1.125
(0.15)
0.5161
Period Momentum Indicator
0.05
(0.02)
(0.02)
(0.30)
0.05
0.06
0.04
0.18
(0.03)
0.32
Rate Of Daily Change
1.04
0.98
0.98
0.99
1.05
1.09
1.03
1.18
0.99
1.08
Day Median Price
1.19
0.85
0.92
25.78
1.01
0.71
1.59
1.08
3.06
4.19
Price Action Indicator
0.04
(0.04)
(0.01)
(0.23)
0.055
0.03
0.045
0.17
(0.04)
0.4
Coefficient Of Variation
(534.32)
(2,436)
1307.72
734.03
(457.21)
(1,905)
812.16
(6,716)
(1,171)
819.33
Mean Deviation
2.16
3.74
9.24
4.79
5.07
3.42
9.87
5.35
2.1
212.1
Jensen Alpha
(0.51)
(0.47)
0.8975
1.93
(1.76)
(0.32)
3.37
(0.11)
(0.30)
99.2
Total Risk Alpha
(0.83)
(0.89)
(0.38)
0.5781
(2.33)
(0.70)
0.5742
(1.00)
(0.56)
20.27
Sortino Ratio
N/A
N/A
0.1336
0.603
N/A
N/A
0.4112
N/A
N/A
8.43
Downside Variance
N/A
N/A
78.42
11.61
N/A
N/A
48.92
N/A
N/A
160.36
Standard Deviation
2.87
6.27
16.64
15.74
7.32
4.58
24.09
8.69
3.0
874.91
Kurtosis
0.3112
8.26
14.93
56.48
2.32
1.07
49.23
14.12
5.16
65.97
Potential Upside
4.13
6.76
21.17
6.93
13.02
7.29
17.16
14.0
5.03
15.67
Treynor Ratio
1.14
(0.11)
0.2755
0.8213
(0.85)
(0.30)
(0.57)
0.3413
(0.57)
1.12
Maximum Drawdown
13.93
34.13
112.24
130.92
41.72
24.08
198.26
57.39
19.0
7142.42
Variance
8.26
39.37
276.93
247.77
53.58
20.93
580.15
75.55
9.02
765465.11
Market Risk Adjusted Performance
1.15
(0.1)
0.2855
0.8313
(0.84)
(0.29)
(0.56)
0.3513
(0.56)
1.13
Risk Adjusted Performance
(0.14)
(0.02)
0.0711
0.1193
(0.17)
(0.03)
0.1089
(0)
(0.06)
0.1083
Skewness
(0.11)
1.43
3.34
7.36
0.6501
0.6897
6.6
2.93
1.45
8.12
Semi Deviation
N/A
N/A
7.77
1.69
N/A
N/A
6.07
N/A
N/A
8.88
Information Ratio
(0.22)
(0.06)
0.0711
0.1305
(0.23)
(0.07)
0.1194
(0.03)
(0.12)
0.1219
Value At Risk
(5.37)
(7.59)
(14.98)
(3.91)
(11.97)
(7.14)
(10.37)
(9.83)
(4.38)
(17.65)
Expected Short fall
N/A
N/A
(15.59)
(5.72)
N/A
N/A
(13.88)
N/A
N/A
(319.17)
Downside Deviation
N/A
N/A
8.86
3.41
N/A
N/A
6.99
N/A
N/A
12.66
Semi Variance
N/A
N/A
60.34
2.85
N/A
N/A
36.9
N/A
N/A
78.88

Sunshine Biopharma Competition Performance Charts

Five steps to successful analysis of Sunshine Biopharma Competition

Sunshine Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sunshine Biopharma in relation to its competition. Sunshine Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Sunshine Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sunshine Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sunshine Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Sunshine Biopharma position

In addition to having Sunshine Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Climate Change Thematic Idea Now

Climate Change
Climate Change Theme
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sunshine Biopharma is a strong investment it is important to analyze Sunshine Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sunshine Biopharma's future performance. For an informed investment choice regarding Sunshine Stock, refer to the following important reports:
How To Invest In Sunshine
Details
Is Sunshine Stock a good investment?
Details
What is Sunshine Biopharma's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Sunshine Biopharma Correlation with its peers.
To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could Sunshine diversify its offerings? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sunshine Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Sunshine Biopharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sunshine Biopharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sunshine Biopharma's market price to deviate significantly from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sunshine Biopharma's market price signifies the transaction level at which participants voluntarily complete trades.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY